Protara Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TARA, updated each market day.
TARA AI Sentiment
AI sees no strong directional signal for Protara Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Protara Therapeutics, Inc. Common Stock
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Sector
Exchange
Market Cap
$287,188,047
Cap Tier
Employees
51
Headquarters
NEW YORK, NY
Listed Since
Jan. 10, 2020
Website
TARA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TARA Volatility
Protara Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
